Hussein Tawbi, MD, PhD
Assistant Professor of Medicine, Clinical & Translational Science



Assistant Professor of Medicine, Clinical & Translational Science UPCI Melanoma and Skin Cancer Program, Co-Director, UPCI Sarcoma Program, Director, UPCI-CTRC

Office Location:
UPMC Cancer Pavilion, Suite 548 5150 Centre Avenue Pittsburgh, PA 15232
Contact Information:
Office Telephone: 412-648-6578
Lab Telephone: 412-648-6579
Email: tawbih@upmc.edu

Education

  • B.Sc - American University of Beirut, 1997
  • MD - American University of Beirut, 2001
  • MSc - University of Pittsburgh, 2007
  • PhD - University of Pittsburgh, 2011

Specialties

  • Chemotherapy Resistance in Metastatic Melanoma
  • Epigenetic Regulation of DNA Repair Mechanisms in Melanoma
  • Sarcoma
  • Early Phase Clinical Trials
  • BRAF Inhibitor Resistance in Metastatic Melanoma
  • Melanoma Brain Metastases

Selected Publications

View Dr. Tawbi's publications on PubMed

  1. A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors. Rodon J, Tawbi HA, Thomas AL, Stoller RG, Turtschi CP, Baselga J, Sarantopoulos J, Mahalingam D, Shou Y, Moles MA, Yang L, Granvil C, Hurh E, Rose KL, Amakye DD, Dummer R, Mita AC. Clin Cancer Res. 2014 Apr 1;20(7):1900-9. doi: 10.1158/1078-0432.CCR-13-1710. Epub 2014 Feb 12.
  2. Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. Tarhini AA, Edington H, Butterfield LH, Lin Y, Shuai Y, Tawbi H, Sander C, Yin Y, Holtzman M, Johnson J, Rao UN, Kirkwood JM. PLoS One. 2014 Feb 3;9(2):e87705. doi: 10.1371/journal.pone.0087705. eCollection 2014.
  3. PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8? T cells induced by melanoma vaccines. Fourcade J, Sun Z, Pagliano O, Chauvin JM, Sander C, Janjic B, Tarhini AA, Tawbi HA, Kirkwood JM, Moschos S, Wang H, Guillaume P, Luescher IF, Krieg A, Anderson AC, Kuchroo VK, Zarour HM. Cancer Res. 2014 Feb 15;74(4):1045-55. doi: 10.1158/0008-5472.CAN-13-2908. Epub 2013 Dec 16.
  4. Calcium carbonate does not affect imatinib pharmacokinetics in healthy volunteers. Tawbi H, Christner SM, Lin Y, Johnson M, Mowrey ET, Cherrin C, Chu E, Lee JJ, Puhalla S, Stoller R, Appleman LR, Miller BM, Beumer JH. Cancer Chemother Pharmacol. 2014 Jan;73(1):207-11. doi: 10.1007/s00280-013-2337-0. Epub 2013 Oct 30.
  5. Calcium carbonate does not affect nilotinib pharmacokinetics in healthy volunteers. Tawbi HA, Tran AL, Christner SM, Lin Y, Johnson M, Mowrey E, Appleman LR, Stoller R, Miller BM, Egorin MJ, Beumer JH. Cancer Chemother Pharmacol. 2013 Nov;72(5):1143-7. doi: 10.1007/s00280-013-2283-x. Epub 2013 Sep 14.
  6. Melanoma brain metastases: an unmet challenge in the era of active therapy. Gorantla V, Kirkwood JM, Tawbi HA. Curr Oncol Rep. 2013 Oct;15(5):483-91. doi: 10.1007/s11912-013-0335-3. Review.
  7. LC-MS/MS assay for the quantitation of the HDAC inhibitor belinostat and five major metabolites in human plasma. Kiesel BF, Parise RA, Tjørnelund J, Christensen MK, Loza E, Tawbi H, Chu E, Kummar S, Beumer JH. J Pharm Biomed Anal. 2013 Jul-Aug;81-82:89-98. doi: 10.1016/j.jpba.2013.03.025. Epub 2013 Apr 9.
  8. Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis. Tawbi HA, Beumer JH, Tarhini AA, Moschos S, Buch SC, Egorin MJ, Lin Y, Christner S, Kirkwood JM. Ann Oncol. 2013 Apr;24(4):1112-9. doi: 10.1093/annonc/mds591. Epub 2012 Nov 21.